{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/optimizing-clinical-trials-pediatric-obesity-treatment#webpage",
"url": "https://www.fortrea.com/insights/optimizing-clinical-trials-pediatric-obesity-treatment",
"name": "Optimizing clinical trials for pediatric obesity treatment",
"description": "Explore this Fortrea white paper focused on optimizing clinical trials for pediatric obesity treatment through patient-centric clinical research strategies and operational innovation. The white paper examines evolving pediatric obesity treatment approaches, recruitment and retention challenges, pediatric obesity drug development, adolescent obesity clinical research, and trial design considerations aimed at improving study participation and clinical trial efficiency. It also highlights operational, medical, and regulatory considerations associated with obesity treatment studies in children and adolescents while outlining approaches designed to reduce patient burden, support family-centered participation, and accelerate pediatric obesity therapeutic development."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Optimizing clinical trials for pediatric obesity treatment",
"item": "https://www.fortrea.com/insights/optimizing-clinical-trials-pediatric-obesity-treatment"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/optimizing-clinical-trials-pediatric-obesity-treatment#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/optimizing-clinical-trials-pediatric-obesity-treatment#webpage"
},
"headline": "Optimizing Clinical Trials for Pediatric Obesity Treatment Through Patient-Centric Research Strategies | Fortrea White Paper",
"description": "Explore this Fortrea white paper focused on optimizing clinical trials for pediatric obesity treatment through patient-centric clinical research strategies and operational innovation. The white paper examines evolving pediatric obesity treatment approaches, recruitment and retention challenges, pediatric obesity drug development, adolescent obesity clinical research, and trial design considerations aimed at improving study participation and clinical trial efficiency. It also highlights operational, medical, and regulatory considerations associated with obesity treatment studies in children and adolescents while outlining approaches designed to reduce patient burden, support family-centered participation, and accelerate pediatric obesity therapeutic development.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-02/optimizing-clinical-trials-for-pediatric-obesity-treatment.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-02-04",
"dateModified": "2025-02-04",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-02/optimizing-clinical-trials-for-pediatric-obesity-treatment.pdf",
"encodingFormat": "application/pdf"
}
}
]
}